Olpha Competitors and Similar CompaniesClear all
Olpha's competitors and similar companies include Oxurion, ANI Pharmaceuticals, Merus and Aerie Pharmaceuticals.
 Olpha Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | |
Founding Date | Founding Date 1972 | Founding Date 1991 | Founding Date 1996 | Founding Date 2003 | Founding Date 2005 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Olaine, LV HQ | Locations Leuven, BE HQ Dublin 8, IE | Locations Baudette, US HQ Oakville, CA Baudette, US | Locations Utrecht, NL HQ Cambridge, US | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US |
Employees | Employees 2,191 | Employees 785% increase | Employees 33813% increase | Employees 260 | Employees 3808% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 626.1 k | Valuation ($) 1.2 b | Valuation ($) 3.6 b | Valuation ($) 722.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €122.2m (FY, 2020) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $883.4m (FY, 2025) | Revenue (est.) $36.1m (FY, 2024) | Revenue (est.) $194.1m (FY, 2021) |
Cost of goods | Cost of goods €44.5m (FY, 2020) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) |
Gross profit | Gross profit €80.1m (FY, 2020) | Gross profit €937k (FY, 2025) | Gross profit N/A | Gross profit $36.1m (FY, 2024) | Gross profit N/A |
Net income | Net income €9.5m (FY, 2020) | Net income (€3.7m) (FY, 2025) | Net income N/A | Net income ($215.3m) (FY, 2024) | Net income ($74.8m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 3.9m | Total funding raised N/A | Total funding raised $ 149.3m | Total funding raised $ 388.6m |
For sources of this data, please see the company profile
View Company Profiles
Oxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyAerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company